SNMMI president weighs in on Lymphoseek approval

03/17/2013 | DOTMed.com

SNMMI President Frederic H. Fahey said Lymphoseek, recently approved by the FDA to map the spread of cancer, will improve diagnoses. The drug "lets you be more confident that you are taking the correct lymph node out," Fahey said. The agent employs a targeted approach to seek out the sentinel lymph node, and it can stay in place longer, which can be more convenient for patients, Fahey said.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY